These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15626899)

  • 1. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease.
    Ringheanu M; Daum F; Markowitz J; Levine J; Katz S; Lin X; Silver J
    Inflamm Bowel Dis; 2004 Nov; 10(6):801-10. PubMed ID: 15626899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.
    Lügering A; Schmidt M; Lügering N; Pauels HG; Domschke W; Kucharzik T
    Gastroenterology; 2001 Nov; 121(5):1145-57. PubMed ID: 11677207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
    Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
    Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
    Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
    Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes.
    Meusch U; Rossol M; Baerwald C; Hauschildt S; Wagner U
    Arthritis Rheum; 2009 Sep; 60(9):2612-21. PubMed ID: 19714631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab Selectively Modulates the Circulating Blood Monocyte Repertoire in Crohn's Disease.
    Slevin SM; Dennedy MC; Connaughton EP; Ribeiro A; Ceredig R; Griffin MD; Egan LJ
    Inflamm Bowel Dis; 2016 Dec; 22(12):2863-2878. PubMed ID: 27824651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
    Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
    Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab and the TNF-alpha system.
    Ebert EC
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G612-20. PubMed ID: 19136378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease.
    Kirman I; Whelan RL; Nielsen OH
    Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):639-41. PubMed ID: 15201575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for).
    Shanahan F
    Inflamm Bowel Dis; 2000 May; 6(2):137-9. PubMed ID: 10833074
    [No Abstract]   [Full Text] [Related]  

  • 12. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
    Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
    Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment.
    Zeissig S; Bojarski C; Buergel N; Mankertz J; Zeitz M; Fromm M; Schulzke JD
    Gut; 2004 Sep; 53(9):1295-302. PubMed ID: 15306588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease.
    Fang L; Pang Z; Shu W; Wu W; Sun M; Cong Y; Liu Z
    Inflamm Bowel Dis; 2018 Jul; 24(8):1733-1744. PubMed ID: 29718341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC; Das KM; Mehta V; Rezac C
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTNF reverse signalling induced by TNFα antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease.
    Derer S; Till A; Haesler R; Sina C; Grabe N; Jung S; Nikolaus S; Kuehbacher T; Groetzinger J; Rose-John S; Rosenstiel PC; Schreiber S
    Gut; 2013 Mar; 62(3):376-86. PubMed ID: 22535372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab therapy increases the frequency of circulating CD16(+) monocytes and modifies macrophage cytokine response to bacterial infection.
    Nazareth N; Magro F; Silva J; Duro M; Gracio D; Coelho R; Appelberg R; Macedo G; Sarmento A
    Clin Exp Immunol; 2014 Sep; 177(3):703-11. PubMed ID: 24816497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
    Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
    J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
    Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.